Clinical Trials
46 results for Bladder Cancer
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243
- Condition: Urothelial Carcinoma, Bladder Cancer
- Intervention: Drug: Durvalumab, Radiation: External Beam Radiotherapy (EBRT), Biological: Bacillus Calmette-Guérin (BCG)
- Study ID: NCT03317158
Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer
- Condition: Bladder Cancer
- Intervention: Drug: Pembrolizumab (MK-3475)
- Study ID: NCT03504163
Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma
- Condition: Bladder Cancer
- Intervention: Drug: BCG instillation therapy, Drug: Sequential BCG and EMDA mitomycin C
- Study ID: NCT03664869
A Phase II Clinical Study of Intravesical Photodynamic Therapy in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Or Patients Who Are Intolerant to BCG Therapy ("Study").
- Condition: Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
- Intervention: Combination Product: TLD-1433 Bladder infusion and Photodynamic Therapy
- Study ID: NCT03945162
Phase II Trial of Intravesical Gemcitabine in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy
- Condition: Urinary Bladder Cancer
- Study ID: NCT05644041
A Clinical Study on the Safety and Efficacy of 9MW2821 in Patients With High-risk Non-muscle-invasive Bladder Cancer (NMIBC) That Have Previously Failed to Intravesical Therapy
- Condition: Bladder Cancer
- Study ID: NCT06551233
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Condition: High-Risk Non-Muscle-Invasive Bladder Cancer
- Study ID: NCT06567743
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
- Condition: Superficial Bladder Cancer
- Study ID: NCT04752722
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscl
- Condition: Non-Muscle Invasive Bladder Neoplasms
- Study ID: NCT06211764
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
- Condition: Non-muscle-invasive Bladder Cancer
- Study ID: NCT05538663
Efficacy and Safety of Pseudomonas Aeruginosa Followed by Postoperative Intravesical Instillation in Patients With Intermediate and High-risk Non-muscle Invasive Bladder Cancer: a Multi-center, Single-arm Clinical Study
- Condition: Bladder Cancer
- Study ID: NCT05975151
A Phase 1b/2, Dose Expansion, Open-label Study to Evaluate Safety and Anti-tumor Activity, of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Condition: Non-muscle Invasive Bladder Cancer
- Study ID: NCT05951179
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Condition: High-risk Non-muscle Invasive Bladder Cancer
- Study ID: NCT06108492
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C Combined with En-bloc Surgery in Treating High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Patients
- Condition: Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Study ID: NCT06696794
A Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants With BCG-unresponsive High Risk Non-muscle-invasive Bladder Cancer
- Condition: Nonmuscle-invasive Bladder Cancer
- Study ID: NCT06971614
An Open-label, Single Arm, Single Center Phase 2 Study of RC48-ADC (IV) in Combination With Gemcitabine(Intravesical) in High Risk NMIBC Subjects (BCG Naïve or BCG Unresponsive) That Expresses HER2 (IHC 1+ and Greater)
- Condition: NMIBC
- Study ID: NCT05943379
A Phase 1, Open-label Trial of AU-011 (Belzupacap Sarotalocan) to Determine the Feasibility and Safety of Intramural Injection With or Without Intratumoral Injection in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
- Condition: Non-muscle-invasive Bladder Cancer
- Study ID: NCT05483868
A Study to Assess the Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy in Patients With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG Therapy
- Condition: Bladder Cancer
- Study ID: NCT06388720
Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
- Condition: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Study ID: NCT06770582
GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
- Condition: Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Study ID: NCT07000084
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susce
- Condition: Non-Muscle Invasive Bladder Cancer
- Study ID: NCT06319820
Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
- Condition: Non-Muscle Invasive Bladder Cancer
- Study ID: NCT06781879
COMparative Prospective Assessment Through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial
- Condition: Non-Muscle Invasive Bladder Cancer
- Study ID: NCT06929286
The Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)
- Condition: Bladder Cancer, Liquid Biopsy, Cystoscopy
- Study ID: NCT07180212
Clinical Application of a Novel Endoscopic Cryoablation Technique Combined With Immunotherapy (TECIC Model) in Bladder-Preserving Therapy for Bladder Cancer
- Condition: Bladder Cancer
- Study ID: NCT07204132
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- Condition: Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
- Study ID: NCT07225127
The Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multi-Center Clinical Study (Truce-LB01)
- Condition: Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
- Study ID: NCT07187635
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
- Condition: Non-muscle Invasive Bladder Cancer (NMIBC)
- Study ID: NCT07187063
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladde
- Condition: Non-Muscle Invasive Bladder Neoplasms
- Study ID: NCT06919965
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADD
- Condition: Non-muscle Invasive Bladder Cancer
- Study ID: NCT07206225
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
- Condition: Bladder Cancer, Urinary Bladder Neoplasms
- Study ID: NCT07222488
Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of Vesical Imaging- Reporting and Data System (VI-RADS) Followed by Primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) Versus Conventional White-light TURBT Plus
- Condition: Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Study ID: NCT05962541
A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer
- Condition: Bladder Cancer
- Study ID: NCT07307456
A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of CG0070 Injection in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer
- Condition: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
- Study ID: NCT07283835
SPICE: Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
- Condition: Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder Carcinoma
- Study ID: NCT07339761
A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US
- Condition: Non-Muscle Invasive Bladder Neoplasms
- Study ID: NCT07309445
The EMPOWER Trial: Evaluating a Home-Based Physical Activity Program (PAP) With the ExerciseRx™ Digital Platform vs. Health Education Group (HEG) in People With Non-Muscle Invasive Bladder Cancer
- Condition: Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Study ID: NCT07302230
A Prospective, Single Center Study of Urinary Tumor DNA-Guided Systemic Immunotherapy in Patients With Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
- Condition: Bladder Cancer, Liquid Biopsy, Immunotherapy
- Study ID: NCT07475403
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
- Condition: Bladder Cancer, Non-muscle Invasive Bladder Cancer
- Study ID: NCT07144319
A Phase II Prospective Single-arm Study of Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer
- Condition: Bladder Cancer
- Study ID: NCT07420517
Optimal Timing of Intravesical GAG Restoration Therapy for BCG-Induced Bladder Toxicity in Patients With Non-Muscle-Invasive Bladder Cancer: A Prospective Randomized Study
- Condition: Urinary Bladder Neoplasms, BCG-Induced Cystitis
- Study ID: NCT07495072
Collection of Urine Samples to Support the Bladder EpiCheck Product Development Studies
- Condition: Suspicion of Bladder Cancer, NMIBC Surveillance
- Study ID: NCT07514143
Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)
- Condition: Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladd
- Study ID: NCT07322263
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
- Condition: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
- Study ID: NCT05521698
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
- Condition: Low Grade Upper Tract Urothelial Carcinoma
- Study ID: NCT07265947
A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy
- Condition: Non Muscle Invasive Bladder Cancer
- Study ID: NCT06972615